Gary M Clifford

List of Publications by Year
in descending order

127 papers	13,399 citations	50276 46 h-index	22832 112 g-index
127 all docs	127 docs citations	127 times ranked	11116 citing authors

#	Article	IF	Citations
1	Human papillomavirus type distribution in invasive cervical cancer and highâ€grade cervical lesions: A metaâ€analysis update. International Journal of Cancer, 2007, 121, 621-632.	5.1	1,452
2	Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infectious Diseases, The, 2007, 7, 453-459.	9.1	1,277
3	Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. The Lancet Global Health, 2020, 8, e180-e190.	6.3	1,092
4	Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. International Journal of Cancer, 2011, 128, 927-935.	5.1	853
5	Cancer Risk in the Swiss HIV Cohort Study: Associations With Immunodeficiency, Smoking, and Highly Active Antiretroviral Therapy. Journal of the National Cancer Institute, 2005, 97, 425-432.	6.3	814
6	Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: A metaâ€analysis. International Journal of Cancer, 2009, 124, 1626-1636.	5.1	811
7	Human papillomavirus types in 115,789 HPVâ€positive women: A metaâ€analysis from cervical infection to cancer. International Journal of Cancer, 2012, 131, 2349-2359.	5.1	706
8	Human Papillomavirus Genotype Distribution in Low-Grade Cervical Lesions: Comparison by Geographic Region and with Cervical Cancer. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1157-1164.	2.5	472
9	Variations in the ageâ€specific curves of human papillomavirus prevalence in women worldwide. International Journal of Cancer, 2006, 119, 2677-2684.	5.1	332
10	Human papillomavirus types among women infected with HIV: a meta-analysis. Aids, 2006, 20, 2337-2344.	2.2	321
11	Estimates of the global burden of cervical cancer associated with HIV. The Lancet Global Health, 2021, 9, e161-e169.	6.3	319
12	Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2018, 18, 198-206.	9.1	294
13	HPV16 E7 Genetic Conservation Is Critical to Carcinogenesis. Cell, 2017, 170, 1164-1174.e6.	28.9	221
14	A metaâ€analysis of anal cancer incidence by risk group: Toward a unified anal cancer risk scale. International Journal of Cancer, 2021, 148, 38-47.	5.1	214
15	Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. Aids, 2008, 22, 2135-2141.	2.2	145
16	Human Papillomavirus Type 16 Genetic Variants: Phylogeny and Classification Based on E6 and LCR. Journal of Virology, 2012, 86, 6855-6861.	3.4	136
17	Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. Aids, 2008, 22, 301-306.	2.2	124
18	Carcinogenicity of Human Papillomavirus (HPV) Types in HIV-Positive Women: A Meta-Analysis From HPV Infection to Cervical Cancer. Clinical Infectious Diseases, 2017, 64, 1228-1235.	5.8	124

#	Article	IF	Citations
19	Risk Factors for Anal Cancer in Persons Infected With HIV: A Nested Case-Control Study in the Swiss HIV Cohort Study. American Journal of Epidemiology, 2013, 178, 877-884.	3.4	116
20	Serologic Response to Oncogenic Human Papillomavirus Types in Male and Female University Students in Busan, South Korea. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1874-1879.	2.5	106
21	Biological activity of probable/possible highâ€risk human papillomavirus types in cervical cancer. International Journal of Cancer, 2013, 132, 63-71.	5.1	106
22	HIV-1â€"related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4+ T-cell lymphocytes. Blood, 2011, 117, 6100-6108.	1.4	99
23	Human Papillomavirus Type 16 and TP53 Mutation in Oral Cancer. Cancer Research, 2004, 64, 468-471.	0.9	98
24	Incidence and Risk Factors of HIV-Related Non-Hodgkin's Lymphoma in the era of Combination Antiretroviral Therapy: A European Multicohort Study. Antiviral Therapy, 2009, 14, 1065-1074.	1.0	92
25	Hodgkin lymphoma in the Swiss HIV Cohort Study. Blood, 2009, 113, 5737-5742.	1.4	92
26	Cervical determinants of anal HPV infection and high-grade anal lesions in women: a collaborative pooled analysis. Lancet Infectious Diseases, The, 2019, 19, 880-891.	9.1	85
27	Human papillomavirus infection in women in Shenzhen City, People's Republic of China, a population typical of recent Chinese urbanisation. International Journal of Cancer, 2007, 121, 1306-1311.	5.1	80
28	Human Papillomavirus 18 Genetic Variation and Cervical Cancer Risk Worldwide. Journal of Virology, 2015, 89, 10680-10687.	3.4	78
29	The relative and attributable risks of cardia and non-cardia gastric cancer associated with Helicobacter pylori infection in China: a case-cohort study. Lancet Public Health, The, 2021, 6, e888-e896.	10.0	78
30	Effect of HIV Infection on Human Papillomavirus Types Causing Invasive Cervical Cancer in Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, 332-339.	2.1	77
31	Niche adaptation and viral transmission of human papillomaviruses from archaic hominins to modern humans. PLoS Pathogens, 2018, 14, e1007352.	4.7	77
32	Epidemiology of anal human papillomavirus infection and high-grade squamous intraepithelial lesions in 29â€‰900 men according to HIV status, sexuality, and age: a collaborative pooled analysis of 64 studies. Lancet HIV,the, 2021, 8, e531-e543.	4.7	77
33	Members of the human papillomavirus type 18 family (alphaâ€7 species) share a common association with adenocarcinoma of the cervix. International Journal of Cancer, 2008, 122, 1684-1685.	5.1	73
34	Risks for Persistence and Progression by Human Papillomavirus Type 16 Variant Lineages Among a Population-Based Sample of Danish Women. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1315-1321.	2.5	72
35	Immunodeficiency and the risk of cervical intraepithelial neoplasia 2/3 and cervical cancer: A nested caseâ€control study in the Swiss HIV cohort study. International Journal of Cancer, 2016, 138, 1732-1740.	5.1	72
36	Human Papillomavirus Infection in Ulaanbaatar, Mongolia: A Population-Based Study. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1731-1738.	2.5	67

#	Article	IF	Citations
37	Type-Specific Anal Human Papillomavirus Prevalence Among Men, According to Sexual Preference and HIV Status: A Systematic Literature Review and Meta-Analysis. Journal of Infectious Diseases, 2019, 219, 590-598.	4.0	67
38	Prevalence of human papillomavirus in women with invasive cervical carcinoma by HIV status in Kenya and South Africa. International Journal of Cancer, 2012, 131, 949-955.	5.1	62
39	Human papillomavirus infection in women with and without cervical cancer in Tehran, Iran. International Journal of Cancer, 2012, 131, E156-61.	5.1	61
40	HPV16 semiquantitative viral load and serologic biomarkers in oral and oropharyngeal squamous cell carcinomas. International Journal of Cancer, 2005, 115, 329-332.	5.1	59
41	Human papillomavirus 16 sub-lineage dispersal and cervical cancer risk worldwide: Whole viral genome sequences from 7116 HPV16-positive women. Papillomavirus Research (Amsterdam,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T	4.5	58
42	Incidence, prevalence and management of lower urinary tract symptoms in men in the UK. BJU International, 2005, 95, 557-562.	2.5	56
43	Human Papillomavirus Antibodies and Future Risk of Anogenital Cancer: A Nested Case-Control Study in the European Prospective Investigation Into Cancer and Nutrition Study. Journal of Clinical Oncology, 2015, 33, 877-884.	1.6	53
44	Human papillomavirus infection in women with and without cervical cancer in Ibadan, Nigeria. Infectious Agents and Cancer, 2010, 5, 24.	2.6	52
45	Mutations in the HPV16 genome induced by APOBEC3 are associated with viral clearance. Nature Communications, 2020, 11, 886.	12.8	52
46	Antibodies against highâ€risk human papillomavirus proteins as markers for invasive cervical cancer. International Journal of Cancer, 2014, 135, 2453-2461.	5.1	51
47	Introduction of a National HPV vaccination program into Bhutan. Vaccine, 2015, 33, 3726-3730.	3.8	51
48	Cancer risk in HIV-infected persons: influence of CD4⁺count. Future Oncology, 2009, 5, 669-678.	2.4	47
49	Seroprevalence of Antibodies against Human Papillomavirus (HPV) Types 16 and 18 in Four Continents: the International Agency for Research on Cancer HPV Prevalence Surveys. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2379-2388.	2.5	46
50	Analysis of human papillomavirus 16 variants and risk for cervical cancer in Chinese population. Virology, 2016, 488, 156-161.	2.4	46
51	Association of <scp>HPV35</scp> with cervical carcinogenesis among women of African ancestry: Evidence of viralâ€host interaction with implications for disease intervention. International Journal of Cancer, 2020, 147, 2677-2686.	5.1	44
52	Human papillomavirus infection in women with and without cervical cancer in Nepal. Cancer Causes and Control, 2010, 21, 323-330.	1.8	41
53	Human papillomavirus infection in Rwanda at the moment of implementation of a national HPV vaccination programme. BMC Infectious Diseases, 2016, 16, 225.	2.9	40
54	FAM19A4/miR124â€2 methylation in invasive cervical cancer: A retrospective crossâ€sectional worldwide study. International Journal of Cancer, 2020, 147, 1215-1221.	5.1	40

#	Article	IF	Citations
55	Global estimates of expected and preventable cervical cancers among girls born between 2005 and 2014: a birth cohort analysis. Lancet Public Health, The, 2021, 6, e510-e521.	10.0	39
56	Urine testing to monitor the impact of HPV vaccination in Bhutan and Rwanda. International Journal of Cancer, 2016, 139, 518-526.	5.1	38
57	Potential impact of a 9-valent HPV vaccine in HPV-related cervical disease in 4 emerging countries (Brazil, Mexico, India and China). Cancer Epidemiology, 2014, 38, 748-756.	1.9	37
58	Urine testing for HPV: rationale for using first void. BMJ, The, 2014, 349, g6252-g6252.	6.0	37
59	Cervical cancer risk in women living with HIV across four continents: A multicohort study. International Journal of Cancer, 2020, 146, 601-609.	5.1	37
60	Residual or Recurrent Precancerous Lesions After Treatment of Cervical Lesions in Human Immunodeficiency Virusâ€“infected Women: A Systematic Review and Meta-analysis of Treatment Failure. Clinical Infectious Diseases, 2019, 69, 1555-1565.	5.8	35
61	Time trends and other sources of variation in Helicobacter pylori infection in mainland China: A systematic review and metaâ€analysis. Helicobacter, 2020, 25, e12729.	3.5	34
62	Re: A Study of the Impact of Adding HPV Types to Cervical Cancer Screening and Triage Tests. Journal of the National Cancer Institute, 2005, 97, 938-939.	6.3	33
63	Prevalence and Risk Factors for Anal Human Papillomavirus Infection in Human Immunodeficiency Virusâ€“Positive Men Who Have Sex with Men. Journal of Infectious Diseases, 2018, 217, 1535-1543.	4.0	33
64	Dried Blood Spot Samples for Seroepidemiology of Infections with Human Papillomaviruses, Helicobacter pylori, Hepatitis C Virus, and JC Virus. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 287-293.	2.5	32
65	Comparison of Two Widely Used Human Papillomavirus Detection and Genotyping Methods, GP5+/6+-Based PCR Followed by Reverse Line Blot Hybridization and Multiplex Type-Specific E7-Based PCR. Journal of Clinical Microbiology, 2016, 54, 2031-2038.	3.9	31
66	Human Papillomavirus 45 Genetic Variation and Cervical Cancer Risk Worldwide. Journal of Virology, 2014, 88, 4514-4521.	3.4	30
67	A caseâ€“control study of <scp>HIV</scp> infection and cancer in the era of antiretroviral therapy in <scp>R</scp>wanda. International Journal of Cancer, 2018, 143, 1348-1355.	5.1	30
68	Human papillomavirus infection in a populationâ€based sample of women in Algiers, Algeria. International Journal of Cancer, 2011, 128, 2224-2229.	5.1	29
69	Human papillomavirus 33 worldwide genetic variation and associated risk of cervical cancer. Virology, 2014, 448, 356-362.	2.4	29
70	Human papillomavirus vaccine coverage in Rwanda: A population-level analysis by birth cohort. Vaccine, 2020, 38, 4001-4005.	3.8	27
71	Genome-wide association study of HPV seropositivity. Human Molecular Genetics, 2011, 20, 4714-4723.	2.9	25
72	Human papillomavirus types in glandular lesions of the cervix: A metaâ€analysis of published studies. International Journal of Cancer, 2013, 132, 248-250.	5.1	25

#	Article	IF	Citations
73	The Utility of Digital Anal Rectal Examinations in a Public Health Screening Program for Anal Cancer. Journal of Lower Genital Tract Disease, 2020, 24, 192-196.	1.9	25
74	Cancer burden attributable to human papillomavirus infection by sex, cancer site, age, and geographical area in China. Cancer Medicine, 2020, 9, 374-384.	2.8	24
75	Determinants of high-grade anal intraepithelial lesions in HIV-positive MSM. Aids, 2018, 32, 2363-2371.	2.2	23
76	Human papillomavirus genotypes in cervical and other HPVâ€related anogenital cancer in Rwanda, according to HIV status. International Journal of Cancer, 2020, 146, 1514-1522.	5.1	23
77	Drug or symptom-induced depression in men treated with alpha1-blockers for benign prostatic hyperplasia? A nested case-control study. Pharmacoepidemiology and Drug Safety, 2002, 11, 55-61.	1.9	22
78	Human papillomavirus infection in Bhutan at the moment of implementation of a national HPV vaccination programme. BMC Infectious Diseases, 2014, 14, 408.	2.9	22
79	Evaluation of the performance of Human Papillomavirus testing in paired urine and clinician-collected cervical samples among women aged over 30Âyears in Bhutan. Virology Journal, 2017, 14, 74.	3.4	22
80	Impact of Human Papillomavirus Vaccination, Rwanda and Bhutan. Emerging Infectious Diseases, 2020, 27, 1-9.	4.3	21
81	Kaposi sarcoma herpes virus antibody response and viremia following highly active antiretroviral therapy in the Swiss HIV Cohort study. Aids, 2010, 24, 2245-2252.	2.2	20
82	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. Clinical Infectious Diseases, 2016, 63, ciw519.	5.8	20
83	Human papillomavirus infection in women with and without cervical cancer in Tbilisi, Georgia. Cancer Epidemiology, 2011, 35, 465-470.	1.9	19
84	Genome-wide association meta-analysis identifies pleiotropic risk loci for aerodigestive squamous cell cancers. PLoS Genetics, 2021, 17, e1009254.	3.5	19
85	Ageâ€specific burden of cervical cancer associated with <scp>HIV</scp>: A global analysis with a focus on <scp>subâ€Saharan</scp> Africa. International Journal of Cancer, 2022, 150, 761-772.	5.1	19
86	Deep brushâ€based cytology in tonsils resected for benign diseases. International Journal of Cancer, 2015, 137, 2994-2999.	5.1	18
87	Evaluation of human-papillomavirus testing and visual inspection for cervical cancer screening in Rwanda. BMC Women's Health, 2018, 18, 59.	2.0	18
88	Clinical performance of methylation as a biomarker for cervical carcinoma inâ€‰situ and cancer diagnosis: A worldwide study. International Journal of Cancer, 2022, 150, 290-302.	5.1	18
89	Judging the carcinogenicity of rare human papillomavirus types. International Journal of Cancer, 2015, 136, 740-742.	5.1	17
90	Burden of anal squamous cell carcinoma, squamous intraepithelial lesions and HPV16 infection in solid organ transplant recipients: A systematic review and meta-analysis. American Journal of Transplantation, 2020, 20, 3520-3528.	4.7	16

#	Article	IF	Citations
91	Cervical cancer screening in rural Bhutan with the care HPV test on self-collected samples: an ongoing cross-sectional, population-based study (REACH-Bhutan). BMJ Open, 2017, 7, e016309.	1.9	15
92	Prevalence of human herpesviruses infections in nonmalignant tonsils: The SPLIT study. Journal of Medical Virology, 2019, 91, 687-697.	5.0	15
93	Incidence and Clearance of Anal Human Papillomavirus (HPV)-16 and HPV-18 Infection, and Their Determinants, Among Human Immunodeficiency Virus-Infected Men Who Have Sex With Men in France. Journal of Infectious Diseases, 2020, 221, 1488-1493.	4.0	15
94	Judging the carcinogenicity of human papillomavirus types by single/multiple infection ratio in cervical cancer. International Journal of Cancer, 2011, 129, 1792-1794.	5.1	14
95	Hepatitis C Virus Seroprevalence in Mongolian Women Assessed by a Novel Multiplex Antibody Detection Assay. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1360-1365.	2.5	14
96	Prevalence of Human Papillomavirus and Estimation of Human Papillomavirus Vaccine Effectiveness in Thimphu, Bhutan, in 2011â€“2012 and 2018. Annals of Internal Medicine, 2020, 173, 888-894.	3.9	14
97	Prevalence of Cervical Human Papillomavirus (HPV) Infection in Vanuatu. Cancer Prevention Research, 2012, 5, 746-753.	1.5	13
98	Prevalence of HPV infection and other risk factors in a Fijian population. Infectious Agents and Cancer, 2014, 9, 14.	2.6	13
99	Human papillomavirus infection among 100 oesophageal cancer cases in the People's Republic of China. International Journal of Cancer, 2007, 121, 1396-1398.	5.1	11
100	Human papillomavirus antibody response following HAART initiation among MSM. Aids, 2017, 31, 561-569.	2.2	11
101	Options for design of real-world impact studies of single-dose vaccine schedules. Vaccine, 2018, 36, 4816-4822.	3.8	11
102	Surveillance systems for monitoring cervical cancer elimination efforts: Focus on HPV infection, cervical dysplasia, cervical screening and treatment. Preventive Medicine, 2021, 144, 106293.	3.4	10
103	Prevalence and risk factors of human polyomavirus infections in non-malignant tonsils and gargles: the SPLIT study. Journal of General Virology, 2018, 99, 1686-1698.	2.9	10
104	Age-Specific Prevalence of Anal and Cervical Human Papillomavirus Infection and High-Grade Lesions in 11 177 Women by Human Immunodeficiency Virus Status: A Collaborative Pooled Analysis of 26 Studies. Journal of Infectious Diseases, 2023, 227, 488-497.	4.0	10
105	Burden of Kaposi sarcoma according to <scp>HIV</scp> status: A systematic review and global analysis. International Journal of Cancer, 2022, 150, 1948-1957.	5.1	9
106	Detection of Circulating HPV16 DNA as a Biomarker for Cervical Cancer by a Bead-Based HPV Genotyping Assay. Microbiology Spectrum, 2022, 10, e0148021.	3.0	9
107	Cervical cancer screening program in Thimphu, Bhutan: population coverage and characteristics associated with screening attendance. BMC Women's Health, 2014, 14, 147.	2.0	8
108	Detection of a large spectrum of viral infections in conjunctival premalignant and malignant lesions. International Journal of Cancer, 2020, 147, 2862-2870.	5.1	8

#	Article	IF	Citations
109	Evaluation of cytology versus human papillomavirus-based cervical cancer screening algorithms in Bhutan. Oncotarget, 2017, 8, 72438-72446.	1.8	8
110	CD4/CD8 ratio and lung cancer risk. Lancet HIV,the, 2017, 4, e103.	4.7	7
111	Phylogenomic Analysis of Human Papillomavirus Type 31 and Cervical Carcinogenesis: A Study of 2093 Viral Genomes. Viruses, 2021, 13, 1948.	3.3	7
112	Antibodies against HPV16E6 oncoprotein in the Swiss HIV cohort study: Kinetics and anal cancer risk prediction. International Journal of Cancer, 2020, 147, 757-765.	5.1	5
113	Cervical cancer in women living in South Africa: a record linkage study of the National Health Laboratory Service and the National Cancer Registry. Ecancermedicalscience, 2022, 16, 1348.	1.1	5
114	Sero-prevalence of 19 infectious pathogens and associated factors among middle-aged and elderly Chinese adults: a cross-sectional study. BMJ Open, 2022, 12, e058353.	1.9	5
115	No risk of drug-associated liver injury with?1-adrenoreceptor blocking agents in men with BPH: results from an observational study using the GPRD. Pharmacoepidemiology and Drug Safety, 2005, 14, 75-80.	1.9	4
116	<scp>Epsteinâ€Barr</scp> virus prevalence among subtypes of malignant lymphoma in Rwanda, 2012 to 2018. International Journal of Cancer, 2022, 150, 753-760.	5.1	4
117	Clifford et al. Respond to "Biological and Clinical Insights From Epidemiologic Research Into HIV, HPV, and Anal Cancer". American Journal of Epidemiology, 2013, 178, 888-889.	3.4	3
118	Molecular Risk Stratification for Anal Cancer Prevention. Clinical Infectious Diseases, 2021, 72, 2164-2166.	5.8	3
119	Prevalence and risk factors for anogenital HPV infection and neoplasia among women living with HIV in China. Sexually Transmitted Infections, 2021, , sextrans-2021-055019.	1.9	3
120	History of tonsillectomy and risk of oropharyngeal cancer. Oral Oncology, 2021, 117, 105302.	1.5	3
121	Fraction of cervical neoplasias due to human papillomavirus 16 and 18 in vaccine trials. International Journal of Cancer, 2008, 122, 719-720.	5.1	2
122	Cervical screening. Aids, 2017, 31, 1045-1046.	2.2	2
123	Author's reply to: Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. International Journal of Cancer, 2011, 129, 1283-1285.	5.1	1
124	Pooled analysis of HPV infection in paired anal and cervical samples, by HIV status. Papillomavirus Research (Amsterdam, Netherlands), 2018, 5, S2-S3.	4.5	1
125	For Anal Cancer, Not All Women Are Equal. American Journal of Gastroenterology, 2021, Publish Ahead of Print, 2140.	0.4	1
126	Determinants of high-grade anal intraepithelial lesions in HIV-positive men having sex with men. Papillomavirus Research (Amsterdam, Netherlands), 2018, 5, S3.	4.5	0

#	Article	IF	Citations
127	Hopes for Prevention of Anal Cancer in Women. Journal of Infectious Diseases, 2019, 221, 1210-1212.	4.0	0